Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

DNA methylation identified as potential anti-TNF response biomarker for RA

DNA methylation identified as potential anti-TNF response biomarker for RA

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds